亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國Athersys  
Athersys公司是一家生物制藥公司，旨在從事開發為提高人類生活質量的產品。公司的產品組合包括干細胞產品MultiStem，這正在發展成為多種疾病的適應癥治療，并正在評估兩個進行中的臨床試驗，并一直在第三臨床試驗授權使用。此外，該公司正在開發藥品來治療如肥胖、某些認知和注意力障礙和嗜睡癥或其他形式的白天過度嗜睡的疾病。公司成立于1995年，總部位于美國.

We are a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapeutic candidates that have the potential to be safer and more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration. Our lead product development programs utilize MultiStem?, a proprietary stem cell product that we believe could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological, and inflammatory and immune disease areas, as well as certain other conditions. MultiStem is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. In addition, we are developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, as well as certain neurological disorders.

Athersys was established in October, 1995, and since 2007 has been a publicly listed company on the NASDAQ exchange (Ticker: ATHX). The company has operations in Cleveland, Ohio and Leuven, Belgium.

We work collaboratively with leading investigators from clinical and research institutions around the world. In recent years, we have worked with over investigators from over 30 leading institutions across the United States and Europe. In addition, we work with leading pharmaceutical and biotechnology companies to accelerate development of our technologies and products. We are committed to scientific excellence, patient safety, and to developing safer and more effective new therapies that can address significant unmet medical needs, and enhance the lives of patients that need help. We believe that this commitment will enable us to create substantial value for our shareholders.